Check Out Our Latest Stock Analysis on PRTA Prothena Stock Down 3.3 % PRTA opened at $10.48 on Wednesday. The company has a market cap of $564.11 million, a P/E ratio of -4.56 and a beta of 0.07 ...

GCs, bar associations, and litigation firms are among the latest to file amicus briefs supporting Perkins Coie in its legal ...

GCs, bar associations, and litigation firms are among the latest to file amicus briefs supporting Perkins Coie in its legal ...

Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinical development.

Just a few days after Biogen abandoned its tau-targeting Alzheimer's disease candidate gosuranemab, Bristol-Myers Squibb has opted into a rival drug, paying $80 million for rights to Prothena's ...

At close: April 10 at 4:00:01 PM EDT ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...